A preclinical study investigates whether blocking a bone-remodeling cytokine improves musculoskeletal health and survival in a progeria mouse model.
Key Takeaways
- Osteocyte-specific deletion of RANKL reversed bone loss in Zmpste24-/- progeroid mice
- RANKL targeting improved muscle function and reduced muscle fibrosis in the mouse model
- Treatment with a neutralizing anti-RANKL antibody increased lifespan in Zmpste24-/- mice